Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease

The goal of this randomised controlled trial is to evaluate the effect of carvedilol (a non-selective beta-blocker) in patients with compensated advanced chronic liver disease under clinically significant portal hypertension or the grey zone of Baveno VII criteria. The main question it aims to answer is: Does carvedilol reduce hepatic decompensation and mortality in these patients despite the absence of varices needing treatment. Researchers will compare carvedilol to no carvedilol to see if carvedilol can prevent hepatic decompensation and mortality. Participants will either take carvedilol or not taking carvedilol for 5 years with regular clinic visit for checkups and investigations, including blood tests, ultrasonography of the liver, upper gastrointestinal endoscopy, transient elastography.

NCT Number	NCT06449339
Lead Sponsor	Chinese University of Hong Kong Collaborators: Singapore General Hospital, University of Palermo, University of Malaya, Shanghai Jiao Tong University School of Medicine, Royal Prince Alfred Hospital, Sydney, Australia
Conditions	Portal Hypertension, Hepatic Decompensation, Advanced Chronic Liver Disease
Enrollment	474 participants
Start Date	2024-07-17
Primary Completion	2031-07-30 (estimated)
Study Completion	2031-07-30 (estimated)
Updated on ClinicalTrials.gov	2025-06-22